TScan Therapeutics (TCRX) director receives 67,000 stock option grant
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
TScan Therapeutics director Katina Dorton received a grant of stock options covering 67,000 shares of Voting Common Stock. The options have an exercise price of $0.9946 per share and expire on May 20, 2036.
The options vest and become exercisable in full on the earlier of May 20, 2027 or the next annual meeting of stockholders, as long as she continues in service. After this grant, she holds 67,000 options directly, and there were no reported share purchases or sales in this filing.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Dorton Katina
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 67,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 67,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 67,000 options
Exercise price: $0.9946 per share
Expiration date: May 20, 2036
+2 more
5 metrics
Option grant size
67,000 options
Stock Option (Right to Buy) granted on May 20, 2026
Exercise price
$0.9946 per share
Exercise price for granted stock options
Expiration date
May 20, 2036
Option expiration for this grant
Post-transaction holdings
67,000 options
Total options held directly after the grant
Vesting date trigger
Earlier of May 20, 2027 or next annual meeting
Full vesting condition subject to continued service
Key Terms
Stock Option (Right to Buy), Voting Common Stock, exercise price, vesting
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Voting Common Stock financial
"underlying_security_title: Voting Common Stock"
exercise price financial
"conversion_or_exercise_price: 0.9946"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The shares subject to this option shall vest and become exercisable in full"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What insider transaction did TScan Therapeutics (TCRX) report for Katina Dorton?
TScan Therapeutics reported that director Katina Dorton received a grant of stock options for 67,000 shares of Voting Common Stock. This is a compensation-related award rather than an open-market share purchase or sale, and no common shares were traded in this filing.
What is the exercise price and term of Katina Dorton’s new TScan (TCRX) stock options?
The granted stock options have an exercise price of $0.9946 per share and expire on May 20, 2036. This means she can choose to buy up to 67,000 shares at that price any time after vesting until the expiration date.
When do Katina Dorton’s TScan Therapeutics (TCRX) options vest and become exercisable?
The options vest and become exercisable in full on the earlier of May 20, 2027 or the next annual meeting of TScan’s stockholders. Vesting is conditioned on her continued service with the company through that vesting date, according to the footnote disclosure.
How many TScan (TCRX) options does Katina Dorton hold after this reported grant?
Following the reported transaction, Katina Dorton holds 67,000 stock options directly. These options each relate to one share of Voting Common Stock and reflect her entire derivative position visible in this specific Form 4, with no additional derivative holdings listed.